Brief: Ovid Therapeutics Announces Collaboration With Graviton Bioscience, Proven Developers Of Selective Rock2 Inhibitors

Ovid Therapeutics

01/05/2023 12:57

Ovid Therapeutics Inc  OVID.O :
    * OVID THERAPEUTICS ANNOUNCES COLLABORATION WITH GRAVITON
BIOSCIENCE, PROVEN DEVELOPERS OF SELECTIVE ROCK2 INHIBITORS
    * OVID THERAPEUTICS INC - TO INVEST $10 MILLION IN PREFERRED
EQUITY IN GRAVITON AND WILL FUND DEVELOPMENT PROGRAMS
    * OVID THERAPEUTICS INC - TRANSACTION HAS NO MILESTONE
PAYMENTS
AND GRAVITON IS ELIGIBLE FOR TIERED DOUBLE-DIGIT ROYALTIES ON
COMMERCIAL SALES
    * OVID THERAPEUTICS - GRAVITON TO BE ELIGIBLE FOR PERCENTAGE
ROYALTIES IN MID-TO HIGH-TEENS BASED ON NET SALES IN TERRITORIES
WHERE PRODUCTS ARE MARKETED
    * OVID THERAPEUTICS - GRAVITON RETAINS RIGHTS TO LICENSED
PRODUCTS
IN ALL FIELDS OF STUDY OUTSIDE OF RARE BRAIN DISORDERS

Source text for Eikon:  ID:nGNX6MKQj0 
Further company coverage:  OVID.O